Home Business & Economics

Business & Economics

On October 16, 2019 Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and WuXi Biologics signed a strategic partnership for Phase III clinical trial production of ARX788 as well ongoing large-scale commercial production of the innovative antibody-drug conjugate.

WuXi Biologics Opens New Facility to Supports Novocodex ADC Manufacturing

Earlier this month China-based Contract Research Organization (CRO) WuXi Biologics started commercial production at the company's new Current Good...

Innate Pharma Confirms Securing Investment to Develop Novel ADC

The French biotechnology company Innate Pharma, which focuses on the discovery as well as the development and commercialization of...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Study Demonstrates Superior Efficacy and Cytotoxicity of Femtogenix’s Sequence-selective DNA-interactive Payload

Data verifying a favorable toxicity profile and potent efficacy of a novel pyrridinobenzodiazepine (PDD) antibody-drug conjugate payload platform in...
MabPlex Building

Frost & Sullivan Awards MabPlex with the 2019 Global Growth Excellence Leadership Award

Based on its recent analysis of the global contract manufacturing services market for antibody-drug conjugate or ADCs, Frost &...
Featured Image - San Diego, CA at night. Courtesy 2019 Fotolia

Zymeworks Wins Best ADC Platform Technology Award for ZymeLink

Zymeworks, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics including bispecific antibodies and bispecific antibody-drug conjugates across a wide range...
Downtown San Diego, CA. Courtesy: 2019 David Cruz/Sunvalley Communication

Abzena to Offer New, Integrated, Clinical Translation Service

Abzena, a life sciences company providing a series of specific serviced for the development of antibody-drug conjugates, earlier this...
The AACR 2019 Annual Meeting - Poster Session during the American Association for Cancer Research (AACR) Annual Meeting, Sunday March 31, 2019. Courtesy: © AACR/Todd Buchanan 2019

Randall Schatzman, Ph.D. to Lead Growth of Immune-Stimulating Antibody Conjugates at Bolt Biotherapeutics

Veteran Executive Randall Schatzman, Ph.D. has been hired as the new Chief Executive Officer and a member of the...

Sutro Biopharma to Receive Milestone Payment from Merck KGaA for Bispecific ADC Candidate

Sutro Biopharma has achieved a milestone under its collaboration and license agreement with the healthcare division of Merck KGaA,...

Comprehensive Service Accelerates Development of ADCs and Reduces Time to Clinic

A new service called ADC Express™services, launched by MilliporeSigma, allows for the rapid production of Antibody-drug Conjugates or ADCs....

Glycotope and Tubulis Sign Agreement for ADC Discovery

Glycotope, a clinical stage biotechnology company, and Tubulis, developing uniquely matched protein drug-conjugates,  have signed a research...